SG10202008378UA - Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab - Google Patents
Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fabInfo
- Publication number
- SG10202008378UA SG10202008378UA SG10202008378UA SG10202008378UA SG10202008378UA SG 10202008378U A SG10202008378U A SG 10202008378UA SG 10202008378U A SG10202008378U A SG 10202008378UA SG 10202008378U A SG10202008378U A SG 10202008378UA SG 10202008378U A SG10202008378U A SG 10202008378UA
- Authority
- SG
- Singapore
- Prior art keywords
- fully
- treatment
- translationally modified
- ocular diseases
- modified anti
- Prior art date
Links
- 208000022873 Ocular disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323285P | 2016-04-15 | 2016-04-15 | |
| US201762442802P | 2017-01-05 | 2017-01-05 | |
| US201762450438P | 2017-01-25 | 2017-01-25 | |
| US201762460428P | 2017-02-17 | 2017-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202008378UA true SG10202008378UA (en) | 2020-10-29 |
Family
ID=60041925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202008378UA SG10202008378UA (en) | 2016-04-15 | 2017-04-14 | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| SG11201808440YA SG11201808440YA (en) | 2016-04-15 | 2017-04-14 | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808440YA SG11201808440YA (en) | 2016-04-15 | 2017-04-14 | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20190127455A1 (ru) |
| EP (1) | EP3442577A4 (ru) |
| JP (2) | JP2019515027A (ru) |
| KR (2) | KR20190003556A (ru) |
| AU (1) | AU2017250797A1 (ru) |
| CA (1) | CA3019665A1 (ru) |
| IL (1) | IL262277A (ru) |
| SG (2) | SG10202008378UA (ru) |
| WO (1) | WO2017181021A1 (ru) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| SG11201808426XA (en) | 2016-04-15 | 2018-10-30 | Univ Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| SG11202005618WA (en) | 2017-12-19 | 2020-07-29 | Akouos Inc | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| US20210093734A1 (en) * | 2018-02-20 | 2021-04-01 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-realted macular degeneration |
| EP3814513A4 (en) * | 2018-06-28 | 2022-04-13 | The University of North Carolina at Chapel Hill | OPTIMIZED CLN5 GENES AND EXPRESSION CASSETTES AND THEIR USE |
| CN113966236A (zh) | 2019-04-03 | 2022-01-21 | 再生生物股份有限公司 | 眼睛病状的基因疗法 |
| TW202106708A (zh) * | 2019-04-24 | 2021-02-16 | 美商銳進科斯生物股份有限公司 | 全人類轉譯後修飾之抗體治療劑 |
| JP2022545967A (ja) | 2019-08-26 | 2022-11-01 | リジェネックスバイオ インコーポレイテッド | 完全ヒト翻訳後修飾抗ＶＥＧＦ Ｆａｂを用いる糖尿病性網膜症の処置 |
| KR20220081365A (ko) | 2019-10-07 | 2022-06-15 | 리젠엑스바이오 인크. | 아데노-연관 바이러스 벡터 약제학적 조성물 및 방법 |
| JP2022553640A (ja) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | 眼障害を処置する方法 |
| CA3198368A1 (en) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Formulations for suprachoroidal administration such as formulations with aggregate formation |
| CA3197342A1 (en) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Gene therapy for ocular manifestations of cln2 disease |
| IL301947A (en) | 2020-10-07 | 2023-06-01 | Regenxbio Inc | Suprachoroid administration formulations, such as gel formulations |
| EP4225270A1 (en) | 2020-10-07 | 2023-08-16 | RegenxBio Inc. | Formulations for suprachoroidal administration such as high viscosity formulations |
| CN116528892A (zh) * | 2020-10-28 | 2023-08-01 | 再生生物股份有限公司 | 用于眼部适应症的载体化抗TNF-α抗体 |
| KR20230121096A (ko) * | 2020-12-18 | 2023-08-17 | 에이씨 이뮨 에스에이 | 항체 전달 |
| CA3209779A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| WO2023196873A1 (en) | 2022-04-06 | 2023-10-12 | Regenxbio Inc. | Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene forsuprachoidal administration |
| TW202345913A (zh) | 2022-04-06 | 2023-12-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如凝膠調配物 |
| TW202404651A (zh) | 2022-04-06 | 2024-02-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如形成聚集體之調配物 |
| WO2024073669A1 (en) | 2022-09-30 | 2024-04-04 | Regenxbio Inc. | Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001029242A2 (en) * | 1999-10-21 | 2001-04-26 | Monsanto Company | Post-translational modification of recombinant proteins produced in plants |
| CA2417508A1 (en) * | 2000-07-26 | 2002-01-31 | Ludwig Institute For Cancer Research | Glycosylated vegf-b and method for increasing the amount of soluble vegf-b |
| MX346002B (es) * | 2009-06-17 | 2017-03-01 | Abbvie Biotherapeutics Inc | Anticuerpos anti-vegf y sus usos. |
| US20130090375A1 (en) * | 2011-10-06 | 2013-04-11 | Cornell University | Virus-mediated delivery of bevacizumab for therapeutic applications |
| TWI698240B (zh) * | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| MY186389A (en) * | 2014-05-13 | 2021-07-22 | Univ Pennsylvania | Compositions comprising aav expressing dual antibody constructs and uses thereof |
-
2017
- 2017-04-14 SG SG10202008378UA patent/SG10202008378UA/en unknown
- 2017-04-14 CA CA3019665A patent/CA3019665A1/en active Pending
- 2017-04-14 AU AU2017250797A patent/AU2017250797A1/en active Pending
- 2017-04-14 WO PCT/US2017/027650 patent/WO2017181021A1/en active Application Filing
- 2017-04-14 SG SG11201808440YA patent/SG11201808440YA/en unknown
- 2017-04-14 KR KR1020187032191A patent/KR20190003556A/ko not_active IP Right Cessation
- 2017-04-14 EP EP17783242.5A patent/EP3442577A4/en active Pending
- 2017-04-14 KR KR1020237043995A patent/KR20240005973A/ko active Search and Examination
- 2017-04-14 JP JP2019505138A patent/JP2019515027A/ja active Pending
- 2017-04-14 US US16/093,363 patent/US20190127455A1/en not_active Abandoned
-
2018
- 2018-10-10 IL IL262277A patent/IL262277A/en unknown
-
2019
- 2019-03-22 US US16/361,884 patent/US20190211091A1/en not_active Abandoned
-
2022
- 2022-03-25 US US17/704,170 patent/US20230057519A1/en active Pending
- 2022-07-06 JP JP2022108815A patent/JP2022153418A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3019665A1 (en) | 2017-10-19 |
| US20190127455A1 (en) | 2019-05-02 |
| IL262277A (en) | 2018-11-29 |
| US20190211091A1 (en) | 2019-07-11 |
| KR20240005973A (ko) | 2024-01-12 |
| JP2022153418A (ja) | 2022-10-12 |
| SG11201808440YA (en) | 2018-10-30 |
| JP2019515027A (ja) | 2019-06-06 |
| US20230057519A1 (en) | 2023-02-23 |
| AU2017250797A1 (en) | 2018-10-25 |
| KR20190003556A (ko) | 2019-01-09 |
| EP3442577A1 (en) | 2019-02-20 |
| EP3442577A4 (en) | 2020-03-25 |
| WO2017181021A1 (en) | 2017-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262277A (en) | Treatment of eye diseases with fully human fab with post-translational modification against vegf | |
| IL273403A (en) | Treatment of eye diseases with FAB against fully humanized post-translationally modified VEGF | |
| HK1246179A1 (zh) | 治療視網膜疾病的方法 | |
| IL274541A (en) | A method for treating diseases of the digestive tract using Tradifitant | |
| EP3351219A4 (en) | MATERIAL FOR THE OPTICAL TREATMENT OF OCULAR DISEASES | |
| IL290069A (en) | Methods for treating eye conditions | |
| IL266275A (en) | Treatment of CNS diseases by sgc stimulators | |
| ZA201903003B (en) | Treatment of neurological diseases | |
| EP3532164A4 (en) | TREATMENT OF DISEASES RELATED TO ACTIVATED IRAQ | |
| EP3340974A4 (en) | METHOD FOR THE TREATMENT OF ILLNESSES | |
| EP3638239A4 (en) | METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH RBP4 USING TRIAZOLOPYRIDINES | |
| IL290863A (en) | Treatment of diabetic retinopathy with a fully post-translationally processed human anti-vegf antigen-binding fragment | |
| IL269698B (en) | Methods for preventing or treating eye diseases | |
| EP3538558A4 (en) | TREATMENT OF ALLERGIC DISEASES WITH A CHIMERAL PROTEIN | |
| IL259381B (en) | Miravegron for the treatment of retinal diseases | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases | |
| PL3689341T3 (pl) | Gabapentyna okulistyczna do leczenia deepitelializacji rogówki | |
| EP3787749A4 (en) | METHODS OF TREATMENT OF RETINAL DISEASES | |
| GB201708076D0 (en) | Treatment of conditions associated with impared glucose control | |
| EP3426280A4 (en) | METHODS OF TREATING NEURODEGENERATIVE DISEASES | |
| PL3302463T3 (pl) | Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu | |
| IL263837A (en) | Treatment of ocular disease | |
| AU2017902737A0 (en) | Treatment of ocular conditions | |
| GB201610938D0 (en) | Treatment of ocular disease | |
| GB201604253D0 (en) | Treatment of genetic diseases |